Patent US5048836A successfully refreshed from Google Patents.
US20030194400A1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Targeted thrombosis
Assignee: Scripps Research Institute
•
Filing: 2002-10-24
•
Granted: —
•
Expires: 2022-10-24
Abstract
Abstract The invention provided compositions and methods to initiate site-specific thrombosis in tumor vasculature. The present invention also provides methods for using the disclosed compositions and methods to treat tumors.
Inventors
- 👤 Cheng Liu
- 👤 Thomas Edgington
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 14:11
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K31/197; A61K31/198; A61K31/33; A61K31/395; A61K31/41; A61K31/4245; A61K31/495; A61K31/505; A61K31/519; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K38/00; A61K38/04; A61K38/05; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/482; A61K38/4846; A61K45/00; A61K45/06; A61K9/00; A61K9/10; A61K9/127; A61P; A61P35/00; C07K2319/00; C07K2319/20; C07K2319/70; C07K2319/74
Claims Analysis
Total Claims: 48
Claim 1
Independent Claim
44 words
1 . A Selective Tissue Vascular Thrombogen comprising a Selective Binding Domain associated with a Tissue Factor polypeptide, wherein the Selective Binding Domain can bind to a channel for blood within a tissue and the human tissue factor can initiate thrombosis within the channel.
Claim 2
Dependent Claim
44 words
1 . A Selective Tissue Vascular Thrombogen comprising a Selective Binding Domain associated with a Tissue Factor polypeptide, wherein the Selective Binding Domain can bind to a channel for blood within a tissue and the human tissue factor can initiate thrombosis within the channel.
Claim 3
Dependent Claim
51 words
2 . The Selective Tissue Vascular Thrombogen of claim 1 wherein the tissue is a lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, benign prostate hyperplasia, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, glioma, or neuroblastoma tumor.
Claim 4
Dependent Claim
17 words
3 . The Selective Tissue Vascular Thrombogen of claim 1 wherein the tissue is a prostate tumor.
Claim 5
Dependent Claim
33 words
4 . The Selective Tissue Vascular Thrombogen of claim 1 wherein the Tissue Factor polypeptide comprises SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.
Claim 6
Dependent Claim
35 words
5 . The Selective Tissue Vascular Thrombogen of claim 1 wherein the Selective Binding Domain comprises a ligand for a cellular receptor, a receptor for a cellular ligand or an inhibitor for a membrane-associated protein.
Claim 7
Dependent Claim
27 words
6 . The Selective Tissue Vascular Thrombogen of claim 1 wherein the Selective Binding Domain binds selectively to endoglin, integrin, VEGF receptor, or Prostate Specific Membrane Antigen.
Claim 8
Dependent Claim
22 words
7 . The Selective Tissue Vascular Thrombogen of claim 1 wherein the Selective Binding Domain is an integrin binding site from fibronectin.
Claim 9
Dependent Claim
25 words
8 . The Selective Tissue Vascular Thrombogen of claim 7 wherein the integrin binding site from fibronectin is a polypeptide from SEQ ID NO: 8.
Claim 10
Dependent Claim
19 words
9 . The Selective Tissue Vascular Thrombogen of claim 1 wherein the Selective Binding Domain is not an antibody.
Claim 11
Dependent Claim
23 words
10 . The Selective Tissue Vascular Thrombogen of claim 1 wherein the Selective Binding Domain comprises an inhibitor of prostate specific membrane antigen.
Claim 12
Dependent Claim
27 words
11 . The Selective Tissue Vascular Thrombogen of claim 10 wherein the inhibitor of prostate specific membrane antigen comprises Asp-β-B-Glu, N-succinyl-glutamic acid, quisqalic acid or 2-(phosphonomethyl)pentanedioic acid.
Claim 13
Dependent Claim
20 words
12 . The Selective Tissue Vascular Thrombogen of claim 1 comprising SEQ ID NO: 9 or SEQ ID NO: 10.
Claim 14
Dependent Claim
64 words
13 . A therapeutic composition comprising a therapeutically effective amount of a Selective Tissue Vascular Thrombogen and a pharmaceutically acceptable carrier, wherein the Selective Tissue Vascular Thrombogen comprises a Selective Binding Domain associated with a Tissue Factor polypeptide, wherein the Selective Binding Domain can bind to a channel for blood within a tissue and the Tissue Factor polypeptide can initiate thrombosis within the channel.
Claim 15
Dependent Claim
64 words
13 . A therapeutic composition comprising a therapeutically effective amount of a Selective Tissue Vascular Thrombogen and a pharmaceutically acceptable carrier, wherein the Selective Tissue Vascular Thrombogen comprises a Selective Binding Domain associated with a Tissue Factor polypeptide, wherein the Selective Binding Domain can bind to a channel for blood within a tissue and the Tissue Factor polypeptide can initiate thrombosis within the channel.
Claim 16
Dependent Claim
49 words
14 . The therapeutic composition of claim 13 wherein the tissue is a lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, benign prostate hyperplasia, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, glioma, or neuroblastoma tumor.
Claim 17
Dependent Claim
15 words
15 . The therapeutic composition of claim 13 wherein the tissue is a prostate tumor.
Claim 18
Dependent Claim
31 words
16 . The therapeutic composition of claim 13 wherein the Tissue Factor polypeptide comprises SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.
Claim 19
Dependent Claim
33 words
17 . The therapeutic composition of claim 13 wherein the Selective Binding Domain comprises a ligand for a cellular receptor, a receptor for a cellular ligand or an inhibitor for a membrane-associated protein.
Claim 20
Dependent Claim
25 words
18 . The therapeutic composition of claim 13 wherein the Selective Binding Domain binds selectively to endoglin, integrin, VEGF receptor, or Prostate Specific Membrane Antigen.
Claim 21
Dependent Claim
20 words
19 . The therapeutic composition of claim 13 wherein the Selective Binding Domain is an integrin binding site from fibronectin.
Claim 22
Dependent Claim
23 words
20 . The therapeutic composition of claim 19 wherein the integrin binding site from fibronectin is a polypeptide from SEQ ID NO: 8.
Claim 23
Dependent Claim
17 words
21 . The therapeutic composition of claim 13 wherein the Selective Binding Domain is not an antibody.
Claim 24
Dependent Claim
21 words
22 . The therapeutic composition of claim 13 wherein the Selective Binding Domain comprises an inhibitor of prostate specific membrane antigen.
Claim 25
Dependent Claim
25 words
23 . The therapeutic composition of claim 22 wherein the inhibitor of prostate specific membrane antigen comprises Asp-β-Glu, N-succinyl-glutamic acid, quisqalic acid, or 2-(phosphonomethyl)pentanedioic acid.
Claim 26
Dependent Claim
16 words
24 . The therapeutic composition of claim 13 wherein the pharmaceutically acceptable carrier is a liposome.
Claim 27
Dependent Claim
18 words
25 . The therapeutic composition of claim 13 that further comprises a Factor VII or Factor VIIa polypeptide.
Claim 28
Dependent Claim
14 words
26 . The therapeutic composition of claim 13 that further comprises a chemotherapeutic agent.
Claim 29
Dependent Claim
24 words
27 . The therapeutic composition of claim 13 wherein the Selective Tissue Vascular Thrombogen comprises SEQ ID NO: 9 or SEQ ID NO: 10.
Claim 30
Dependent Claim
62 words
28 . A method of treating a solid tumor in an animal that comprises administering a therapeutically effective amount of a Selective Tissue Vascular Thrombogen comprising a Selective Binding Domain associated with a Tissue Factor polypeptide, wherein the Selective Binding Domain can bind to a channel for blood within a tumor and the Tissue Factor polypeptide can initiate thrombosis within the channel.
Claim 31
Dependent Claim
62 words
28 . A method of treating a solid tumor in an animal that comprises administering a therapeutically effective amount of a Selective Tissue Vascular Thrombogen comprising a Selective Binding Domain associated with a Tissue Factor polypeptide, wherein the Selective Binding Domain can bind to a channel for blood within a tumor and the Tissue Factor polypeptide can initiate thrombosis within the channel.
Claim 32
Dependent Claim
45 words
29 . The method of claim 28 wherein the tumor is a lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, melanoma, glioma, or neuroblastoma tumor.
Claim 33
Dependent Claim
14 words
30 . The method of claim 28 wherein the tumor is a prostate tumor.
Claim 34
Dependent Claim
14 words
31 . The method of claim 30 wherein the thrombosis leads to tumor necrosis.
Claim 35
Dependent Claim
30 words
32 . The method of claim 28 wherein the tissue factor polypeptide comprises SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.
Claim 36
Dependent Claim
32 words
33 . The method of claim 28 wherein the Selective Binding Domain comprises a ligand for a cellular receptor, a receptor for a cellular ligand or an inhibitor for a membrane-associated protein.
Claim 37
Dependent Claim
24 words
34 . The method of claim 28 wherein the Selective Binding Domain binds selectively to endoglin, integrin, VEGF receptor, or Prostate Specific Membrane Antigen.
Claim 38
Dependent Claim
19 words
35 . The method of claim 28 wherein the Selective Binding Domain is an integrin binding site from fibronectin.
Claim 39
Dependent Claim
22 words
36 . The method of claim 35 wherein the integrin binding site from fibronectin is a polypeptide from SEQ ID NO: 8.
Claim 40
Dependent Claim
16 words
37 . The method of claim 28 wherein the Selective Binding Domain is not an antibody.
Claim 41
Dependent Claim
20 words
38 . The method of claim 28 wherein the Selective Binding Domain comprises an inhibitor of prostate specific membrane antigen.
Claim 42
Dependent Claim
24 words
39 . The method of claim 38 wherein the inhibitor of prostate specific membrane antigen comprises Asp-β-Glu, N-succinyl-glutamic acid, quisqalic acid or 2-(phosphonomethyl)pentanedioic acid.
Claim 43
Dependent Claim
18 words
40 . The method of claim 28 wherein the Selective Tissue Vascular Thrombogen is administering in a liposome.
Claim 44
Dependent Claim
19 words
41 . The method of claim 28 that further comprises administering a therapeutically effective amount of a chemotherapeutic agent.
Claim 45
Dependent Claim
15 words
42 . The method of claim 41 wherein the chemotherapeutic agent comprises methotrexate or doxorubicin.
Claim 46
Dependent Claim
23 words
43 . The method of claim 28 that further comprises administering a therapeutically effective amount of an inhibitor of prostate specific membrane antigen.
Claim 47
Dependent Claim
24 words
44 . The method of claim 43 wherein the inhibitor of prostate specific membrane antigen comprises Asp-β-Glu, N-succinyl-glutamic acid, quisqalic acid or 2-(phosphonomethyl)pentanedioic acid.
Claim 48
Dependent Claim
23 words
45 . The method of claim 28 wherein the Selective Tissue Vascular Thrombogen comprises SEQ ID NO: 9 or SEQ ID NO: 10.
References Cited (Backward Citations)
US4196265A
Cited
US4554101A
Cited
US5288641A
Cited
US5139941A
Cited
US5017556A
Cited
US5589173A
Cited
US5437864A
Cited
US5110730A
Cited
US5223427A
Cited
US4975369A
Cited
US5183756A
Cited
US4938949A
Cited
US5242813A
Cited
US5504064A
Cited
US5504067A
Cited
US5346991A
Cited
US5589363A
Cited
US6036955A
Cited
US6004555A
Cited
US5374617A
Cited
US6150508A
Cited
US5968915A
Cited
US5880112A
Cited
US5804602A
Cited
US5863536A
Cited
US5795877A
Cited
US6156321A
Cited
US5902817A
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.